分享产品介绍 评论(0)
物种
Human分子别名
IL-5,rRtIL-5,EDF,BCDFII,TRFAccession
P05113表达序列
Ile20-Ser134表达宿主
E.coli分子量
13.3kDa
纯度
>95% by SDS-PAGE内毒素含量
<1EU/μg活性
< 0.5ng/ml标记
Unconjugated标签
No Tag性状
Lyophilized Powder缓冲体系
20mM Tris, pH9.0
溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
文献引用
1、Milburn M V. et al. (1993) A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Nature. 363(6425): 172-176.
2、Woodcock J M. et al. (1994) Three residues in the common beta chain of the human GM-CSF, IL-3 and IL-5 receptors are essential for GM-CSF and IL-5 but not IL-3 high affinity binding and interact with Glu21 of GM-CSF. EMBO J. 13 (21): 5176-85.
Interleukin 5 (IL-5) is predominantly produced by Th2 cells to regulate differentiation and proliferation of eosinophils. As the major cytokine in eosinophil development, IL-5 induces eosinophil migration, activation, and survival. The primary source of IL-5 is TH2 lymphocytes, but mast cells are also a source in the airways. IL-5 is increased in bronchial biopsies and BAL fluid and serum from symptomatic asthmatic patients, knockout of IL-5 in mice eliminates AHR and eosinophilia, and overexpression or treatment with rIL-5 results in asthma-like lung histopathology. Blockade of IL-5 in humans with mepolizumab, an anti-IL-5 antibody, decreases eosinophils in the sputum and general circulation, and in asthma patients exhibiting hypereosinophilia and resistance to steroid therapy mepolizumab reduces exacerbations.
生物活性
Measured in a cell proliferation assay using TF-1 human erythroleukemic cells, the EC50 for this effect is less than 0.5 ng/ml.
电泳
- 1μg (R: reducing condition, N: non-reducing condition).
评论(0)